Study S000549

Effect of GLP-1 on Angiogenesis, Angiosafe Type 2 Diabetes Study 1

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02686177
Acronym: ANGIOSAFE 1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 50
Start: 2016-05-18
Primary completion: 2017-08-08
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Conditions: Type 2 Diabetes
Interventions: DRUG:Liraglutide; DRUG:Metformin or sulfonylurea
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:2015-002930-35; NIH:2015

Registered primary outcomes

Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group [At 1 month]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006583	Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study. Gaborit B, The Journal of clinical endocrinology and metabolism	2020	Randomized trial	PMID 31589290 DOI	cites ClinicalTrials.gov:NCT02686177; registry reference DERIVED:31589290